Litigation Details for Bayer AG v. Mayne Pharma LLC (D. Del. 2017)
Bayer AG v. Mayne Pharma LLC (D. Del. 2017)
| Docket | 1:17-cv-01037 | Date Filed | 2017-07-27 |
| Court | District Court, D. Delaware | Date Terminated | 2017-12-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 8,071,577 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bayer AG v. Mayne Pharma LLC
Details for Bayer AG v. Mayne Pharma LLC (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-07-27 | External link to document | |||
| 2017-07-27 | 12 | the Commissioner of Patents and Trademarks for Patent/Trademark Number 8,071,577 B2. (etg) (Entered: … 21 December 2017 1:17-cv-01037 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2017-07-27 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,071,577 B2. (ceg) (Entered:… 21 December 2017 1:17-cv-01037 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Bayer AG v. Mayne Pharma LLC, 1:17-cv-01037: Litigation Summary and Patent Analysis
Bayer AG v. Mayne Pharma LLC, No. 1:17-cv-01037, was a Hatch-Waxman patent case filed in the U.S. District Court for the District of Delaware concerning Mayne Pharma's abbreviated new drug application for a generic version of Bayer's Xarelto product, rivaroxaban. Bayer asserted patent rights covering rivaroxaban and sought to prevent FDA approval or commercial launch before the asserted patents expired. The case ended without a reported merits judgment, and the public docket does not disclose a judicial finding that Mayne's proposed product infringed or that the asserted patents were invalid.
What drug was at issue in Bayer AG v. Mayne Pharma?
The case concerned rivaroxaban, the active pharmaceutical ingredient in Xarelto.
| Item | Details |
|---|---|
| Brand product | Xarelto |
| Active ingredient | Rivaroxaban |
| Brand sponsor | Janssen Pharmaceuticals, Inc., and Bayer affiliates |
| Relevant Bayer entity | Bayer AG |
| Regulatory pathway | ANDA under the Hatch-Waxman Act |
| Court | U.S. District Court for the District of Delaware |
| Case number | 1:17-cv-01037 |
| Filing year | 2017 |
| Case type | Abbreviated New Drug Application patent litigation |
| Defendant | Mayne Pharma LLC |
| Patent dispute | Generic rivaroxaban approval and launch timing |
Xarelto is an oral factor Xa inhibitor approved for several indications, including prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of deep-vein thrombosis and pulmonary embolism, and prevention of venous thromboembolism after certain orthopedic surgeries. The product's commercial importance made generic entry strategically significant for Bayer and its commercialization partner Janssen.
What patents did Bayer assert against Mayne Pharma?
Bayer's Xarelto litigation generally involved patents covering rivaroxaban itself, pharmaceutical compositions, and methods of treatment. The principal patent associated with early generic-rivaroxaban litigation was U.S. Patent No. 7,157,456.
U.S. Patent No. 7,157,456
| Field | Information |
|---|---|
| Patent number | U.S. 7,157,456 |
| Subject matter | Oxazolidinone compounds, including rivaroxaban |
| Patent family | Rivaroxaban compound patent family |
| Listed product | Xarelto |
| Original expiration | Generally reported in 2021 |
| Extended expiration | Reported through December 2024 after pediatric exclusivity |
| Strategic role | Core compound protection for rivaroxaban |
The '456 patent was the principal barrier to a conventional generic rivaroxaban launch. The patent's expiration period was extended by pediatric exclusivity. That extension was particularly important because it moved the effective regulatory barrier beyond the original patent term.
Bayer's Xarelto patent estate also included later-issued patents and indication-specific rights. The exact patents asserted against Mayne must be distinguished from patents listed in the Orange Book for Xarelto at different times. Orange Book listings can change as patents issue, expire, are delisted, or are replaced by later-listed patents.
What was Mayne Pharma's Paragraph IV position?
Mayne's ANDA filing would have required certifications addressing patents listed for Xarelto in the FDA's Orange Book. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.
Bayer's complaint was the statutory response to that certification. Under 21 U.S.C. § 355(j)(5)(B)(iii), a timely patent-infringement action generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court orders.
The litigation therefore had two immediate commercial consequences:
- It created a regulatory stay against final FDA approval of Mayne's ANDA, unless the stay expired or was otherwise lifted.
- It shifted the commercial launch question from FDA review to patent validity, infringement, and settlement terms.
A Paragraph IV filing does not establish that a patent is invalid or that the proposed product is noninfringing. It only creates the statutory mechanism for challenging the listed patents before generic launch.
What was the procedural history of the case?
The case was filed in the District of Delaware in 2017. It followed the standard Hatch-Waxman sequence:
| Stage | Event |
|---|---|
| ANDA filing | Mayne submitted an ANDA for generic rivaroxaban |
| Paragraph IV notice | Mayne notified Bayer and the relevant brand stakeholders of its patent certifications |
| Complaint | Bayer filed the patent-infringement action in 2017 |
| Regulatory consequence | The litigation implicated the statutory FDA approval stay |
| Case resolution | The public docket reflects resolution without a reported merits trial decision |
| Final judicial outcome | No reported invalidity, unenforceability, or noninfringement judgment against the asserted Bayer patents |
The case did not produce a widely reported claim-construction ruling or final trial opinion. No public decision from the litigation established that the '456 patent or any other asserted Xarelto patent was invalid or unenforceable.
Was there a settlement agreement in Bayer v. Mayne Pharma?
The case was resolved through a court-recorded disposition rather than a reported merits judgment. The public docket does not provide the full economic and commercial terms of any private settlement.
The commercially material provisions in a Hatch-Waxman settlement would typically include:
- The earliest permitted Mayne launch date.
- Whether Mayne received a license before patent expiration.
- Whether Mayne could launch upon a specified court ruling involving another generic challenger.
- Restrictions on authorized-generic or supply arrangements.
- Treatment of later-issued patents.
- Mutual releases and dismissal terms.
Without public disclosure of the agreement's complete terms, the docket cannot establish whether Mayne received a fixed launch date, a contingent entry right, or another commercial arrangement.
The absence of a public merits ruling means the case should not be treated as precedent on the validity or scope of Bayer's rivaroxaban patents.
What is the Orange Book status of Xarelto?
Xarelto is an FDA-approved drug with patent listings in the Orange Book. The central listed patent protection for rivaroxaban involved Bayer's compound patent and later patents addressing additional aspects of the product.
Regulatory and exclusivity timeline
| Date or period | Event |
|---|---|
| 2011 | FDA approval of Xarelto for initial U.S. indications |
| 2017 | Bayer filed the Mayne Pharma patent case |
| 2021 | Original term of the key rivaroxaban compound patent generally reached its end |
| December 2024 | Pediatric-exclusivity-adjusted protection for the core patent was generally reported to end |
| Post-2024 | Generic entry became more commercially feasible, subject to remaining patents, FDA approval, settlements, and product-specific barriers |
Patent expiration and generic availability are separate issues. An ANDA applicant may obtain FDA approval before commercial launch if a patent settlement or license restricts launch. Conversely, approval does not eliminate the risk posed by later-issued or method-of-use patents.
How strong was Bayer's patent estate against Mayne?
Bayer's position was strongest with respect to the core compound patent because a valid compound patent can block products containing the active ingredient regardless of a generic manufacturer's excipients, tablet color, packaging, or manufacturing site.
Strengths
- The '456 patent covered the active pharmaceutical ingredient rather than only a narrow formulation.
- Rivaroxaban was the defining active ingredient in the proposed generic product.
- The patent had extended protection through pediatric exclusivity.
- The Orange Book listing created a statutory approval stay after Bayer filed suit.
- Bayer and Janssen had substantial commercial and litigation resources.
Limitations
- Compound patents are vulnerable to invalidity challenges based on anticipation, obviousness, written description, and enablement.
- A Paragraph IV challenger can seek to narrow the practical value of a patent by establishing noninfringement or invalidity.
- Later method-of-use patents may not block a generic label that carves out the patented indication.
- Settlement terms can permit an earlier launch even while patents remain in force.
- Patent expiry does not protect the brand from substitution once an approved generic becomes commercially available.
The absence of a merits decision prevents a definitive assessment of how the District of Delaware would have construed or upheld the asserted claims.
Did the case involve formulation patents or method-of-use patents?
The principal commercial issue was compound protection for rivaroxaban. Xarelto's broader patent estate included rights that could address formulation, dosage regimen, and approved uses.
Formulation protection
Formulation patents can cover:
- Tablet composition.
- Excipients and dissolution characteristics.
- Particle size or solid-state properties.
- Manufacturing processes.
- Food-effect or bioavailability characteristics.
A formulation patent is usually narrower than a compound patent. Its practical value depends on whether the generic applicant uses the claimed formulation and whether the applicant can design around the claims.
Method-of-use protection
Method-of-use patents can cover particular patient populations, dosages, treatment durations, or indications. An ANDA applicant may use a section viii statement or a label carve-out for certain patented uses, provided the resulting label does not encourage infringement of the patented method.
For Xarelto, method-of-use analysis was important because the brand had multiple indications approved at different times. Generic entry for one indication does not necessarily authorize use for every patented indication.
Which companies challenged Xarelto patents?
Xarelto faced broad generic interest because of its large prescription base and high sales before core patent expiry. Multiple generic manufacturers filed ANDAs or became involved in related patent litigation, including major Indian and U.S. generic companies.
The relevant competitive group included:
- Mayne Pharma.
- Teva Pharmaceuticals.
- Mylan.
- Lupin.
- Actavis and related entities.
- Other ANDA applicants pursuing rivaroxaban tablets.
The existence of parallel cases created potential coordination issues for launch timing. A settlement with one applicant did not necessarily determine the rights of other challengers, but a first-to-file applicant could have a commercial advantage depending on the ANDA filing sequence and the status of 180-day generic exclusivity.
What generic launch risks did Bayer face?
Bayer's principal risk was an at-risk launch before final resolution of patent disputes. If Mayne launched before patent expiry and later lost, Bayer could seek damages, injunctive relief, or other remedies. If Mayne prevailed, Xarelto could face rapid price erosion and pharmacy substitution.
Launch scenarios
| Scenario | Commercial result |
|---|---|
| Patent upheld and no license | Mayne launch delayed until patent expiry |
| Patent invalidated | Mayne could launch after FDA approval, subject to appeal and other patents |
| Noninfringement ruling | Mayne could launch if no remaining legal barrier existed |
| Settlement with fixed entry date | Mayne launches on the agreed date |
| Settlement with contingent entry | Launch depends on another litigation or regulatory event |
| At-risk launch | Mayne launches before final patent resolution, accepting significant damages exposure |
| Patent expiry after pediatric extension | Broad generic entry becomes possible absent surviving patents |
The most important commercial date was not simply the original expiration of the '456 patent. The relevant date included pediatric exclusivity, any later-listed patents, and the terms of any confidential or partially disclosed settlement.
How does Mayne's case compare with broader Xarelto patent litigation?
Mayne's case was one component of a larger patent program around rivaroxaban. Bayer used coordinated litigation to manage multiple ANDA challenges in the District of Delaware. The cases shared the commercial objective of preserving Xarelto's protected revenue period while testing the validity and scope of generic applicants' certifications.
Unlike a trial judgment, a settlement disposition does not resolve the underlying patent questions for the market. It establishes contractual rights between the parties. Other ANDA applicants may remain free to pursue separate invalidity or noninfringement theories unless they are bound by a common settlement or collateral estoppel applies.
What revenue exposure did the litigation create?
Xarelto was one of Bayer's largest pharmaceutical products and a major source of pharmaceutical revenue. The product also generated significant revenue for Janssen under the parties' commercialization arrangement.
The financial exposure had several components:
- Loss of branded sales after generic substitution.
- Price erosion from multiple rivaroxaban manufacturers.
- Potential reduction in market share before patent expiry.
- Litigation damages if a generic launched at risk.
- Settlement economics, including any license payments or launch concessions.
- Continued revenue from indications or formulations protected by surviving patents.
Because the case ended without a reported damages judgment, no case-specific damages award was established.
Key Takeaways
- Bayer AG v. Mayne Pharma LLC, No. 1:17-cv-01037, was a District of Delaware Hatch-Waxman case involving generic rivaroxaban, the active ingredient in Xarelto.
- Bayer's principal strategic protection was U.S. Patent No. 7,157,456, a core compound patent associated with rivaroxaban.
- The original patent term was extended by pediatric exclusivity, with protection generally reported through December 2024.
- Mayne's Paragraph IV position triggered patent litigation and the statutory FDA approval stay.
- The case ended without a reported merits decision establishing patent validity, infringement, or noninfringement.
- Public docket materials do not disclose the full commercial terms of the parties' resolution.
- Xarelto's generic-entry risk depended on compound patents, later-listed patents, method-of-use rights, FDA approval, and settlement restrictions.
- The case should be analyzed as part of Bayer's broader coordinated defense of Xarelto against multiple ANDA challengers.
FAQs
What was the case number for Bayer v. Mayne Pharma?
The case number was 1:17-cv-01037 in the U.S. District Court for the District of Delaware.
Was Mayne Pharma allowed to launch generic Xarelto immediately?
The public case record does not establish an immediate launch right. The litigation and any settlement terms governed Mayne's commercial entry, subject to FDA approval and remaining patent rights.
Did Bayer win the Xarelto patent case against Mayne?
There was no reported merits judgment awarding Bayer a final infringement victory against Mayne. The case was resolved through a docketed disposition.
What patent protected the active ingredient in Xarelto?
U.S. Patent No. 7,157,456 was the principal compound patent associated with rivaroxaban and Xarelto's core patent protection.
Did the Mayne case invalidate Bayer's Xarelto patents?
No reported decision in the case invalidated Bayer's Xarelto patents. The public record does not establish a final invalidity ruling.
References
-
Bayer AG v. Mayne Pharma LLC, No. 1:17-cv-01037, U.S. District Court for the District of Delaware, docket records.
-
U.S. Patent No. 7,157,456. (2006). Oxazolidinone derivatives. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
-
U.S. Food and Drug Administration. (n.d.). Xarelto (rivaroxaban) prescribing information. https://www.accessdata.fda.gov
-
Hatch-Waxman Act, 21 U.S.C. § 355(j).
More… ↓
